Microplastics in Otitis Media With Effusion Material

March 25, 2024 updated by: Kerem Kökoğlu

Evaluation of Microplastics Presence in Otitis Media With Effusion Material

Microplastic rate is increasing ib athmosphere. They can be found in lung, kidney, heart, even placenta. Otitis media with effusion (OME) is a clinical condition that is ver common in children. Biofilms are blamed in the pathogenesis of OME. Microplastics can include biofilms. Importance of microplastics for potential pathogens and their toxicity aspects should be enlighted with studies. This study aims to investigate presency of microplastics in middle ear fluid of patients with OME.

Study Overview

Detailed Description

This study was planned prospectively. With ethical approvel, patients who were followed by bilateral OME at least for three months or one-sided OME at least for 9 months were enrolled to the study. Patients with craniofacial anomaly, cleft palate, had history of previous ear surgery were excluded. They were operated as paracentesis and ventilation tube implementation (VTI). An informed consent form was obtained from them and their parents.

Operation: Surgical indication was made according to disease duration and/or hearing loss. Patients were operated under general anesthesia. Paracentesis was made from posteroinferior quadrant of tympanic membrane. Glu material was trapped in the suction tube and tranferred to glass tubes immediately (Figure 1). For this, glass syringe and 0.9 % serum physiologic were used. Samples were sent from right and left ear seperately. Microplastics determination was made in Enviromental Engineering Labaratory of Faculty of Engineering.

Microplastics Determination Method: It applied according to Prada et. al report (11). Fragments, except blood clots, were washed with a jet of filtered distilled water inside the laminar flow hood to remove any surface contamination and all samples were weighed inside closed glass flasks to the nearest 0.1 mg (Sartorius, Entris, Germany). A method for preparing biological samples for Nile Red staining, previously developed and tested, was followed [16]: (i) incubation for 24 h at 60 °C (Oasis™ Benchtop IR CO2 Incubator, Caron, OH, USA) in 30 mL of 10% KOH (w/v, ≥85%, Labchem, PA, USA); (ii) at 24 h, the temperature was raised to boiling point and the solution immediately filtered on glass fiber filter membrane (1.2 µm pore, Whatman® GF/C, Little Chalfont, Buckinghamshire, UK) mounted in a vacuum glass filtration system; (iii) 100 mL of boiling filtered distilled water was filtered to remove soaps; (iv) 10 mL of acetone was added to the cup for 10 min; (v) an additional 10 mL of acetone was filtered to remove lipophilic matter; (vi) 0.5-1 mL of 0.01 mg mL-1 of Nile Red (microscopy grade, Sigma-Aldrich, St. Louis, MO, USA) was added to the cup for 5 min; (vii) 50 mL of distilled water was filtered; and (viii) stored in glass Petri dishes kept inside cardboard boxes for a week to dry at room temperature (20 °C).

Contamination Control Measures Strict contamination control measures were conducted in all phases, namely by: (i) wearing cotton lab coats and clean gloves; (ii) working in the laminar flow hood in a clean room, maintained by cleaning with ethanol in paper towels followed by cleaning with a duster that attracts and traps dust particles and paper fibers; (iii) filtering all solutions (1.2 µm pore, Whatman® GF/C); (iv) using glass and metal materials; (v) decontaminating glass materials by submerging them in 10% HNO3 for at least 30 min and rinsing with distilled water; (vi) additionally cleaning glass Petri dishes with a N2 air jet; (vii) burning glass microfiber filter membranes at 450 °C for 3 h; (viii) cleaning the cup of the filtration system between samples by dipping it for 15 s in a solution (first batch: acetone, second batch: 30% HNO3) followed by dipping in distilled water; (ix) keeping sample containers closed as much as possible with glass lids, caps, or aluminum foil; and (x) conducting procedural blanks (solutions without samples exposed to sample preparation procedures) for each batch. Each samples were tested by three times for verification. In addition, microplastics were evaluated in serum psyisologic to prevent contamination.

Study Type

Observational

Enrollment (Estimated)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Kayseri, Turkey, 38039
        • Recruiting
        • Erciyes University Medical School
        • Contact:
        • Contact:
        • Sub-Investigator:
          • Mehmet I Şahin, Assoc. Prof, M.D.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Any age, patients with bilateral OME at least 3 months or unilateral OME at least 9 months

Description

Inclusion Criteria:

  • patients who were followed by bilateral OME at least for three months or one-sided OME at least for 9 months were enrolled to the study

Exclusion Criteria:

  • Patients with craniofacial anomaly, cleft palate, had history of previous ear surgery were excluded

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
patient group
patient group has formed as operated patients because of OME A paracentesis and ventilation tube insertion will be performed them. After paracentesis, effusion otitis media will be trapped and sampled for microplastic analysis.
a paracentesis will be done to tympanic membrane. Glu will be aspirated and trapped.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Microplastic presence
Time Frame: from March 2024 to April 2024
They will be commented as yes / no. Microplastics Determination Method: It applied according to Prada et. al report. Fragments, except blood clots, were washed with a jet of filtered distilled water inside the laminar flow hood to remove any surface contamination and all samples were weighed inside closed glass flasks to the nearest 0.1 mg (Sartorius, Entris, Germany). A method for preparing biological samples for Nile Red staining, previously developed and tested, was followed.
from March 2024 to April 2024

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Mehmet I Şahin, Assoc Prof., TC Erciyes University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 20, 2024

Primary Completion (Estimated)

April 20, 2024

Study Completion (Estimated)

April 20, 2024

Study Registration Dates

First Submitted

March 10, 2024

First Submitted That Met QC Criteria

March 14, 2024

First Posted (Actual)

March 18, 2024

Study Record Updates

Last Update Posted (Actual)

March 27, 2024

Last Update Submitted That Met QC Criteria

March 25, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • 2023/209
  • self-funding (Other Identifier: Erciyes University)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Otitis Media With Effusion

Clinical Trials on ventilation tube insertion

3
Subscribe